Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
214
resultados
Última actualización
12/03/2026 [06:53:00]
Resumen de: AU2024263334A1
Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.
Resumen de: WO2024226779A1
The present disclosure describes lipid nanoparticle (LNP) compositions and uses thereof, e.g. for treating ocular-related disorders or diseases.
Resumen de: WO2024228632A1
The description of the invention discloses a stable polymer-lipid nanoparticle for drug binding and delivery comprising a core containing polylactic-co-glycolic acid (PLGA) and polyvinyl alcohol (PVA) and a core envelope containing a mixture of lipids: 1,2-dipalmitoyl-sn-glycero-3- phosphocholine (DDPC), cholesterol and the ammonium salt of 1,2- distearoyl-sn-glycero-3-phosphoethanolamine-N -amino(polyethylene glycol)-2000 (DSPE-PEG(2000)NH2 and a method for producing such particles.
Resumen de: MX2025013218A
Compounds are provided having the following Structure (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R<sup>1</sup>, R<sup>1</sup>, L<sup>1</sup>, L<sup>2</sup>, L<sup>2a</sup>, L<sup>2b</sup>, and A are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.
Resumen de: WO2024229321A1
This disclosure relates to delivery vehicles comprising payload molecules, e.g., mRNA for the treatment of cystic fibrosis (CF). Nucleic acid therapeutics (e.g., mRNAs) when administered in vivo encode cystic fibrosis transmembrane conductance regulator (CFTR). Nucleic acid therapeutics (e.g., mRNAs) of the disclosure increase and/or restore deficient levels of CFTR expression and/or activity in subjects.
Resumen de: WO2024228964A1
The present application, in certain aspects, pertains to methods and compositions for the treatment of cancers, such as undifferentiated pleomorphic sarcoma or leiomyosarcoma, using : (a) a composition comprising nanoparticles comprising an mTOR inhibitor (such as a limus drug, e.g, sirolimus or a derivative thereof) and an albumin; and, optionally, (b) an anti-PD-1 antibody.
Resumen de: EP4706637A1
According to one arrangement, a drug(1) for genetic modification according to an arrangement is a drug for performing genome editing on a gene in a hematopoietic stem cell. The drug for genetic modification contains a genome editing molecule(2) and a lipid nanoparticle(3) encapsulating the genome editing molecule. The lipid nanoparticle includes a lipid membrane(30) having a lumen. The lipid composition contains at least a first lipid (FFT-10) and a second lipid (FFT-20) in the lipid composition. The amount of the second lipid is larger than that of the first lipid, the total amount of the first lipid and the second lipid is 40 mol% or less, and the total amount of the cationic lipid is 60 mol% or less.
Resumen de: EP4706690A1
The present application relates to the field of biological medicines, in particular to a phytic acid-based ternary complex bionic nano material. The ternary complex bionic nano material is composed of phytic acid, metal ions and a protein/polypeptide. The ternary complex is formed by connecting the protein/polypeptide with phytic acid using metal cations as a cation bridge. According to the application, the phytic acid ternary complex having different protein/polypeptide groups is synthesized by using various metal ions as bridges. A novel nano diagnosis and treatment probe having high biocompatibility is constructed, which can be reassembled and gathered for a long time at a tumor part, and has coordination-loaded imaging/therapeutic metal ions. The functions of long-acting tumor imaging, treatment or integrated diagnosis and treatment can be achieved, and the solution can be expected to be used as a novel bionic nano material in the field of biomedicine. In addition, the preparation process of the nano material is simple, and industrial production is easy to implement.
Resumen de: WO2024229147A2
Aspects of the disclosure relate to compositions comprising encapsulated immunotoxins and methods for using the encapsulated immunotoxins. The encapsulated immunotoxins may be capable of reaching otherwise difficult to target tissues, such as the brain, and may resist denaturation and degradation prior to reaching the targeted tissue.
Resumen de: MX2025013065A
Suspension formulations of nanoparticles of clobetasol propionate are described. The suspensions can be used therapeutically to treat skin and ocular burns; to enhance wound healing; to prevent or reduce hypertrophic scarring/keloids; to treat allergic rhinitis/sinusitis, asthma, inner ear disorders including hearing loss, tinnitus, or vertigo, tenosynovitis, tendinitis, enthesitis or arthritis.
Resumen de: EP4706645A1
The present invention relates to PEGylated reconstituted high-density lipoprotein nanoparticles having the effect of preventing or treating neurodegenerative diseases. Specifically, the present invention relates to nanoparticles and a method for producing the same, a phospholipid layer of the produced nanoparticles being protected by PEG due to PEG-lipid or a derivative thereof being included in the process of preparing a fluid comprising a hydrophobic material and a fluid comprising a hydrophilic material. The PEGylated nanoparticles have the ability to avoid the rejection mechanism of the immune response in the body while maintaining the existing transport ability across the blood-brain barrier, thereby having excellent stability and exhibiting long-term pharmacological effect due to high circulation ability in the body, and thus can be effectively utilized as a drug or a drug carrier.
Resumen de: EP4706644A1
The present invention relates to: reconstituted high-density lipoprotein nanoparticles comprising cholesterol; and a composition for preventing or treating Alzheimer's disease and cancer, the composition comprising the nanoparticles. Specifically, the reconstituted high-density lipoprotein nanoparticles comprising cholesterol according to the present invention have an excellent cell influx rate and promote cholesterol efflux from cells, thus having a cancer cell killing effect, and can therefore be used for preventing or treating cancer.
Resumen de: EP4706660A1
The present invention relates to a pharmaceutical composition comprising a telomerase activator and nanoparticles for drug delivery and a composition containing same for the prevention, alleviation, or treatment of hair loss. More specifically, the present invention relates to a composition effective for promoting the regeneration and growth of hair follicles, the composition being a nanoliposome, nano-liposome, nano-silica particle, or nano-bubble composition in which drugs such as the plant extract component TA-65 and a derivative thereof that increase telomerase activity, and the telomerase activating compound GPC and a derivative thereof are encapsulated
Resumen de: EP4707386A1
The present invention provides an artificial viral capsid modified with a compound containing a fluorine atom. The artificial viral capsid is formed by self-assembly of multiple subunits, wherein the subunit comprises a β-annulus peptide of tomato bushy stunt virus, a group derived from a fluorine-containing compound, and a divalent linking group that links the β-annulus peptide to the group derived from a fluorine-containing compound; and the divalent linking group is linked to a C-terminus of the β-annulus peptide.
Resumen de: AU2024260092A1
The present disclosure in some aspects relates generally to nanoparticle compositions for oxygen delivery, method of use thereof, and method of preparation thereof. The present disclosure in some aspects relates generally to topical formulations capable of delivering oxygen to a tissue and methods of their use for treating diseases, such as hypoxemia.
Resumen de: WO2024228630A1
The description of the invention discloses a composition comprising 17- AAG and staurosporine for use in the treatment of melanoma, non-small cell lung cancer, pancreatic cancer, mammary gland tumours or gliomas, and a stable polymer-lipid nanoparticle for drug binding and delivery, consisting of a core containing polylactic-co-glycolic acid (PLGA) and polyvinyl alcohol (PVA) and a core envelope containing a mixture of lipids: 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DDPC), cholesterol and the ammonium salt 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N - amino(polyethylene glycol)-2000 (DSPE-PEG(2000)NH2J.
Resumen de: CN121641162A
本发明公开了一种关于LNP设计、制备及应用全过程的集成数据库及构建方法，集成数据库，包括：物性参数数据集，代表适用于LNP制备的原料物质，每一个物性参数数据对应一个原料物质；工艺参数数据集，代表LNP制备过程中的工艺参数，每一类工艺参数数据包含多个不同数值的工艺参数；配方组成数据集，包括多个配方组成数据，每个配方组成数据包括多个不同的物性参数数据与多个工艺参数数据；以及，递送效率数据集，包括多个递送效率数据，每个递送效率数据与一个配方组成数据对应。本发明整合LNP系统设计‑制备‑应用全过程中涉及的参数，将影响LNP性能的变量全部转化为数值类型的特征参数，便于后续的高通量条件筛选与数据挖掘，可以极大的促进LNP制备过程的自动化改造与LNP性能优化。
Resumen de: CN121622940A
本发明涉及生物医学和基因治疗技术领域，具体涉及一种Krit1 mRNA在治疗脑海绵状血管畸形中的应用；KRIT1 mRNA通过脂质纳米颗粒形成LNP@Krit1 mRNA进行递送，可以应用于制备预防和/或治疗脑海绵状血管畸形试剂、制备恢复脑血管内皮细胞的屏障功能试剂和制备减少或抑制脑部血管的渗漏和出血试剂；在体外和体内CCM模型中均能有效恢复Krit1功能，显著改善血管病变，具有良好的开发前景和临床转化价值。
Resumen de: CN121622610A
本发明涉及一种基于三组分脂质纳米颗粒(LNP)的新型基因药物递送系统及其制备方法和应用。该三组分LNP由阳离子脂质、结构脂质和聚合物缀合脂质三种成分组成，通过精确配比优化，实现了在简化成分的同时，保持了高效递送性能。与传统四组分LNP相比，该三组分LNP在制备过程中减少了化学成分的种类，从而显著降低了生产工艺的复杂性和成本，使其更适合于大规模工业生产。此外，由于减少了成分种类，三组分LNP的生物相容性得以提升，潜在的免疫原性和毒性风险降低，具有更高的安全性。
Resumen de: CN121622616A
本发明属于药物递送与肿瘤免疫治疗技术领域，具体涉及一种溶瘤病毒载囊泡及其制备方法和应用。所述制备方法为：溶瘤腺病毒与血小板在含前列腺素E2的缓冲体系中共孵育，诱导形成内膜封装体；在36‑38℃、4‑6%CO2条件下激活释放囊泡，经300g、2000g、10000g、100000g梯度离心收集。所述溶瘤病毒载囊泡粒径50‑200nm，表面含CD41、CD61及P‑selectin，可实现溶瘤病毒的长循环与肺靶向递送，适用于制备治疗乳腺癌及乳腺癌肺转移的药物，抑瘤效果显著。
Resumen de: CN121627601A
本发明公开了一种阳离子脂质化合物及其构建的脂质纳米颗粒、药物组合物和用途，由该阳离子脂质化合物（式I）所构建的脂质纳米颗粒具有较小的粒径和较低的多形貌指数，并且对药物分子具有极高的封装效率，同时能够在保持高表达强度的前提下，将其中负载的mRNA药物精准递送至肝脏，且在其它器官，例如肺、心脏和肾脏中几乎不表达，在脾脏少量表达，在癌症治疗中具有重要的临床应用意义。
Resumen de: CN121627719A
本发明公开一种近红外光热分子、纳米粒子、可注射近红外光热水凝胶及其在制备抗肥胖药物中的应用。所述近红外光热分子的结构式为：。本发明进行分子结构设计获得具有强近红外吸收、明亮的近红外二区荧光发射及高光热稳定性的近红外光热分子；并通过纳米沉淀法将近红外光热分子用两亲性聚合物封装为球形纳米粒子，进一步将其与温敏基质材料混合制备得到可皮下注射的近红外光热水凝胶，经近红外照射后，可显著诱导脂肪细胞凋亡，同时促进白色脂肪向米色脂肪转化，具有高效抗肥胖作用；且可通过近红外二区荧光成像实时追踪水凝胶降解、药剂分布及治疗过程，提升了治疗的可控性与精准度。整个系统展现出良好的生物相容性，在抗肥胖领域具有突出的应用潜力。
Resumen de: CN121627824A
本发明涉及生物医药技术领域，尤其涉及一种功能化脂肽及其制备方法、功能化脂肽辅助的核酸类药物脂质纳米递送系统及其应用，功能化脂肽为官能团化聚乙二醇‑脂质与功能化杂化多肽的部分或全部裸露的氨基通过点击化学反应或迈克尔加成反应形成的化合物；功能化杂化多肽为N‑羟基琥珀酰亚胺‑聚乙二醇‑基团与功能化多肽的部分或全部裸露的氨基通过酯化反应形成的化合物。本发明脂肽制备过程简单、毒性低，脂肽辅助的核酸类药物脂质纳米递送系统可以实现在体外和体内对siRNA、mRNA及DNA等多种核酸分子的高效率递送其在各种疾病的治疗作用。
Resumen de: CN121622725A
本发明涉及一种环状RNA用于制备核酸药物的应用。本发明经实验研究证实，环状 RNA circPde5a 可用于制备长效减肥降糖核酸药物；将 circPde5a 递送至靶组织（如胰岛组织、白色脂肪组织）后，可通过调控靶组织代谢相关通路，实现减肥与降糖的双重效果。同时，该 circPde5a 还可与现有治疗手段协同使用。
Nº publicación: CN121622615A 10/03/2026
Solicitante:
国家纳米科学中心
Resumen de: CN121622615A
本发明属于生物技术领域，公开了一种脂质体纳米颗粒及其制备方法和应用。本发明提供的脂质体纳米颗粒的制备方法中，首先通过特定粒径的金属纳米颗粒与RNA进行共孵育，接着再取该水相溶液与包括脂质体组合物的有机相溶液进行混合，以形成具有NPs‑RNA复合内核以及脂质体外壳的核壳结构的脂质体纳米颗粒，该脂质体纳米颗粒在内体的生理条件下对于内体的膜结构具有优秀的破坏作用，能够高效地介导RNA的内体逃逸，具有良好的内体逃逸效率，以实现RNA至细胞质的高效递送，从而实现更好的治疗或免疫效果，在RNA药物和/或RNA疫苗的制备中具有巨大的应用潜力。
BOPI
Sede Electrónica
